Drug Trial Radar · NCT05955872
A Study Evaluating the Relative Bioavailability and Food Effect of a Tablet Formulation of VX-147
Last checked: Nov 19, 2026Latest source record: Sep 13, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
21
Actual
Start
Jul 19, 2023
Primary completion
Sep 2, 2023
Study completion Sep 2, 2023
Sponsor
- Lead sponsor
- Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
- Sponsor type
- Industry
- First posted
- Jul 21, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the relative bioavailability (BA) and the effect of food on the pharmacokinetics (PK), and the safety and tolerability of VX-147 test tablet formulation.
Conditions
- Focal Segmental Glomerulosclerosis (FSGS)
Interventions
VX-147Drug
Tablets for oral administration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Observed Plasma Concentration (Cmax) of VX-147 Test Compared to VX-147 ReferenceTime frame: From Day 1 up to Day 16
- Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of VX-147 Test Compared to VX-147 ReferenceTime frame: From Day 1 up to Day 16
- Cmax of VX-147 Test Compared Under Fed Versus Fasted StateTime frame: From Day 1 up to Day 16
- AUC(0-inf) of VX-147 Test Compared Under Fed Versus Fasted StateTime frame: From Day 1 up to Day 16
Locations
1 site in 1 country. Site status is shown where the registry gives one.
ICON Salt Lake City
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.